Cost of the Cervical Cancer Screening Program at the Mexican Social Security Institute
Costo del Programa de Detección Oportuna de Cáncer Cervical en el Instituto Mexicano del Seguro Social
Víctor Granados-García, M Phil,(1) Yvonne N Flores, PhD,(2,3) Ruth Pérez, MA,(4) Samantha E Rudolph, BA,(2,5) Eduardo Lazcano-Ponce, DSc,(6) Jorge Salmerón MD, DSc.(2,6)
(1) Unidad de Investigación Epidemiológica y en Sistemas de Salud, Área de envejecimiento, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. México DF, México.
(2) Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social. Cuernavaca, Morelos, México.
(3) Department of Health Policy and Management, Fielding School of Public Health and Jonsson Comprehensive Cancer Center. University of California. Los Angeles, California, USA.
(4) Coordinación Delegacional de Abastecimiento y Equipamiento, Delegación Morelos, Instituto Mexicano del Seguro Social. Cuernavaca, Morelos, México.
(5) UC Berkeley-UC San Francisco Joint Medical Program, University of California. Berkeley, California, USA.
(6) Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, México.
Objective. To estimate the annual cost of the National Cervical Cancer Screening Program (CCSP) of the Mexican Institute of Social Security (IMSS).
Materials and methods. This cost analysis examined regional coverage rates reported by IMSS. We estimated the number of cytology, colposcopy, biopsy and pathology evaluations, as well as the diagnostic test and treatment costs for cervical intraepithelial neoplasia grade II and III (CIN 2/3) and cervical cancer. Diagnostic test costs were estimated using a micro-costing technique. Sensitivity analyses were performed.
Results. The cost to perform 2.7 million cytology tests was nearly 38 million dollars, which represents 26.1% of the total program cost (145.4 million). False negatives account for nearly 43% of the program costs.
Conclusion. The low sensitivity of the cytology test generates high rates of false negatives, which results in high institutional costs from the treatment of undetected cervical cancer cases.
Key words: costs and cost analysis; cytology; screening; cervical cancer; Mexico.
Objetivo. Estimar el costo anual del Programa Nacional de Detección Oportuna de Cáncer Cervical en el Instituto Mexicano del Seguro Social (IMSS).
Material y métodos. Este análisis de costos examinó las distintas coberturas por región reportadas por el IMSS. Se estimó el número de citologías, colposcopías, biopsias y evaluaciones de patología y los costos de pruebas de diagnóstico y de tratamientos por neoplasia cervical intraepitelial de grado II y III (NIC 2/3) y cáncer cervical. Los costos de las pruebas de diagnóstico se estimaron utilizando una técnica de microcosteo. Se llevó a cabo un análisis de sensibilidad.
Resultados. El costo de realizar 2.7 millones de citologías fue de 38 millones de dólares, lo que representa 26.1% del costo total del programa (145.4 millones). Los falsos negativos corresponden a casi 43% de los costos del programa.
Conclusiones. La baja sensibilidad de la citología genera un alto número de falsos negativos que resultan en costos elevados para la institución por el tratamiento de estos casos no detectados.
Palabras clave: costos y análisis de costos; citología; detección; cáncer cervical; México.
For most countries around the world, including Mexico, cervical cytology, or the Papanicolaou (Pap) test, serves as the principal diagnostic tool for the detection of cervical cancer. The health and economic implications of this test have been analyzed for health care systems throughout Latin America.1-4 Although the Pap test has helped to significantly reduce the burden of disease from cervical cancer in a number of high-income countries, as suggested by strong epidemiologic data,5-7 high incidence rates and related deaths persist in many middle to low-income Latin American nations.8,9 In some cases, these findings may be explained by the socioeconomic disparities and high levels of marginalization throughout the region.10,11
A cytology program has large infrastructural and resource requirements. On top of specialized training for technicians and pathologists, as well as managing appropriate follow-up and treatment, an effective quality assurance program is necessary. Since cervical cytology is largely a subjective test, both an internal and external quality control program is essential to assure the proper clinical performance of the test. Cytology is also labor intensive, adding to the resource requirements of such a program. For these reasons, public health programs have historically struggled to maintain effective cervical cancer control programs that employ the Pap test in settings with limited resources and competing priorities.12
Although numerous studies suggest that screening programs can reduce the rates of cervical cancer by 60 to 90%,13,14 cervical cancer remains the second leading cause of death for Mexican women due to cancer11 despite the fact that Mexico instituted a screening program in 1974. Overall, the number of cervical cancer related deaths in Mexico peaked in 1989 and have decreased since, settling at 9.2 deaths per 100 000 women in 2008.15
The cost of the Pap test and confirmatory tests (colposcopy and biopsy) have been estimated in several economic evaluations of cervical cancer prevention programs in Mexico.2,16-18 However, these reports do not provide sufficient information to evaluate the methods used to identify, measure, and assign unitary costs to cytology testing as well as to other diagnostic procedures like colposcopy and biopsy. Furthermore, estimates of the overall costs of the cervical cancer screening programs (CCSP) at the Instituto Mexicano del Seguro Social (IMSS) have not been reported. Data concerning the use of diagnostic tests for cervical cancer detection in Mexico indicate that a significant number of Pap tests are performed in Mexico each year, yet the health and economic impact of these tests on the health system, are unknown.
The aim of this study was to estimate the costs associated with performing a Pap test, the accompanying confirmatory tests, and the total annual CCSP costs, from the health care provider perspective. Our estimates also include the treatment costs for undetected cases of cancer. A secondary aim was to provide a detailed explanation of how these costs were estimated. IMSS is the largest provider of health services in Mexico and offers health insurance to workers in the formal sector of the economy and their families; approximately 47% of the Mexican population is insured by IMSS.19 A better understanding of the costs associated with the IMSS national CCSP will be useful to policy and decision makers.
Materials and methods
We performed a cost analysis of the IMSS national CCSP taking into account that approximately 2.7 million Pap tests were performed in a population of 9.16 million women between the ages of 25 and 64, who were insured by IMSS in 2010.* The coverage rates of the IMSS CCSP in the north, center and south were also used to examine possible cost variations by region. The direct medical costs of the IMSS CCSP were calculated considering the following: a) screening costs, which include the costs to obtain the cervical sample and the laboratory costs to determine and report the cytology diagnosis; b) the costs to confirm a positive cytology test, which include the costs to perform a colposcopy exam and taking a biopsy if necessary, and the laboratory costs to determine a biopsy-confirmed diagnosis, c) the cost to treat cervical intraepithelial neoplasia (CIN) 2/3 or cervical cancer cases resulting from the true positive (TP) or false negative (FN) diagnoses.
Estimates of outcomes and costs were obtained using previously published information17,20,21 and from IMSS CCSP administrative sources* (table I). This analysis was conducted from the perspective of IMSS with a time horizon of one year, during which all the screening and follow-up activities were assumed to occur. Because the study's timeframe is a single year, health outcomes and costs were not discounted. Estimates were calculated assuming that each woman had only one Pap test and that 37.1% of the women who received a TP or false positive (FP) diagnosis were lost to follow-up, based on previous findings.21 Additionally, although screening coverage rates varied by region, we used the same sensitivity, specificity, and cervical cancer prevalence to determine our cost and outcome estimates.20,21
Cost of diagnostic tests
A retrospective, observational study design was used to measure the goods and services used for each cost category and process. Micro-costing techniques, which included a time and motion (TAM) study, were employed to identify the time, quantity, labor, and equipment costs associated with each of the cervical cancer diagnosis processes at IMSS.22 Data were obtained at the IMSS Hospital General Regional No. 1 in the state of Morelos during 2007. The following categories were used to determine the cytology, colposcopy, biopsy and pathology costs: a) staff or personnel costs; b) supply costs, which include medical supplies, treatment materials, etc.; c) capital costs; and d) overhead costs.
Staff costs were calculated by multiplying the amount of time spent on each task by each worker, by the hourly rate that each employee is paid to perform the task. Rates of pay were obtained from the Integrated System of Personnel Administration (Sistema Integral de Administración de Personal, or SIAP) of the IMSS Personnel Department in Morelos.23 We assumed that 10% of the salary cost of the personnel involved in the CCSP can be attributed to administrative personnel. Supply costs were determined by multiplying the units or amounts of goods consumed, by the price paid to purchase each good. These prices were obtained from the IMSS purchasing catalog of items,24 which is issued by the institutional supply system, and market prices when necessary. The IMSS information system for acquisitions25 was used to determine the annual equipment and furniture costs, at a discount rate of 3%.22 The annual building costs, including the costs of land and construction (as well as insurance costs) minus the depreciation costs were also estimated. Land values were estimated using the District Catalog of Real Estate and Supplies for the General Directorate of Works and Real Estate Assets for IMSS. Capital and overhead costs were obtained from the IMSS Office of Construction, Conservation, and Equipment, from the Morelos IMSS administrative offices.25 A discount rate of 3% over 50 years was used to annuitize capital expenditures.22 Fixed costs were allocated to the hospital services based on the percentage of space used in each area where CCSP activities take place. The average cost of the cytology, colposcopy, and biopsy procedures were estimated by dividing the total costs to perform each test by the number of procedures performed. The number of procedures was obtained from the monthly hospital productivity reports. All costs are reported in 2013 USD.
Cost to treat CIN 2/3 and cervical cancer cases
We also estimated the associated cost to treat women with precancerous lesions (CIN 2/3) or cervical cancer. To calculate the treatment costs of the IMSS CCSP, we estimated the number of CIN 2/3 and cervical cancer treatments and assigned them a cost based on previously published cancer treatment costs.17
Costs based on cytology test performance
The number of true positives (TP), false negatives (FN), false positives (FP) and true negatives (TN) and the associated costs of these outcomes were calculated. We used previously reported estimates of the sensitivity (40%) and specificity (97%) of the Pap test, the rate of TP and FP cases that are lost to follow-up at IMSS,20 as well as the reported prevalence of cervical cancer at IMSS (13 cases per 1 000 women)21 to estimate these outcomes (table I).
The number of TP was obtained by multiplying the prevalence rate of 0.013 times the total number of women screened (n= 2 705 436), to determine the number of women with CIN 2/3 or cervical cancer in this population (n= 35 171). This number was then multiplied by the reported sensitivity of the Pap test (0.40) to obtain the number of women who should be correctly identified as having disease (n= 14 068). The number of colposcopies and biopsies associated with TP were estimated assuming that 62.9% of women in this group returned for these follow-up procedures and treatment (n= 8 449) and 37.1% did not.20 Additionally, we assumed that among the total TP cases, 88% of women received a diagnosis of CIN 2/3 and 12% received a cervical cancer diagnosis, based on previously published findings. To estimate the costs of the TP cases, we determined the number of women diagnosed with CIN 2/3 or cervical cancer for each region. For example, of the 14 068 total TP cases that were identified, 1 688 (12%) were diagnosed with cervical cancer and 12 380 were found to have CIN 2/3 (88%) (figure 1). We then multiplied the number of CIN 2/3 and cervical cancer cases by their corresponding treatment costs, and then added the screening costs (table I).
FN were estimated by subtracting the total number of TP (n= 14 068) from the estimated number of cases (n= 35 171). The costs associated with FN diagnoses were estimated by multiplying the total number of women who received a FN by the cost to treat a case of cervical cancer or CIN 2/3. Again, we assumed 88% of women would have CIN 2/3 and 12% would have cervical cancer.21 We multiplied the estimated number of cases by their respective treatment cost, and then added the total screening costs. The number of FP was estimated by subtracting the TN from the total number of women without disease (n= 2 670 265). To estimate the FP costs we assumed that 39% of women had a colposcopy with biopsy, as well as the corresponding pathology procedures and 24% had a colposcopy evaluation without a biopsy.21 Additionally, we assumed that 62.9% of women in this group returned for these follow-up procedures and treatment (n= 50 388) and 37.1% (n= 29 640) did not.20 The number of TN was determined by subtracting the total number of cases (n= 35,171) from the total number of women screened (n= 2 705 436) and multiplying that number by the specificity of the cytology test (97%). The costs associated with a TN diagnosis were estimated by multiplying the total number of TN by the cost to perform a cytology test. Figure 1 provides a description of how the costs of the IMSS CCSP were estimated based on the number of TP, FN, FP and TN diagnoses.
A deterministic sensitivity analysis was conducted to investigate the effects of certain parameters on the total costs of the IMSS CCSP. We examined the effect that changes in the coverage of the program (ranging from 20 to 40%) and variations in the sensitivity of the Pap test (ranging from 35 to 60%) have on the number of FN, TP, TN and FP diagnoses. We also varied the total and staff costs of the cytology, colposcolpy and biopsy tests to determine the extent to which these variations (±20%) affect the total program costs. A three-way sensitivity analysis was also conducted that considered high vs. low costs of tests and treatment, a range of 20 to 40% for the coverage rate of the IMSS CCSP, as well as a Pap test sensitivity that ranged from 35 to 60% based on previously published results.20,21 We did not use the IMSS unitary costs lists for this analysis because they do not report the costs of colposcopy and biopsy.26 Due to a lack of information on the variability of the cost to treat CIN 2/3 and cervical cancer cases, we used a lower and upper range of ±20% for the base case treatment costs.
The cost of a single cytology test, colposcopy without biopsy, colposcopy with biopsy, and pathology were estimated to be 14.04, 39.80, 69.01 and 26.27 USD, respectively. Staff costs were found to be the most important component for each of these four procedures, representing between 73-79% of the total cost of these diagnostic tests. The second most important contributor to the cost of these tests were supply costs for cytology (11%), overhead costs for colposcopy, and capital costs (10%) for pathology (table II). The total cost to perform approximately 2.7 million Pap tests was almost 38 million USD, which represents 26.1% of the total IMSS CCSP costs, estimated to be 145.4 million USD per year. We estimated that 99 248 confirmatory tests were performed with a cost of nearly 4.6 million USD, representing 3.1% of the total costs of the IMSS CCSP. The cost to treat the estimated 35 171 cases of CIN 2/3 or cervical cancer was 102.8 million USD, which accounts for the largest proportion (70.7%) of the costs of the program (table III).
The cost of the IMSS CCSP was also examined based on the resulting outcomes from the performance of the cytology test. The total cost to treat the 21 103 false negatives was nearly 62 million USD, which represents the largest proportion (42.6%) of the total program cost. The cost to diagnose and treat the 14 068 true positives was estimated to be 42.2 million USD (29% of the total program costs). The 2 590 157 women who were found to be true negatives cost 36.37 million USD, representing 25.1% of the total program costs, and finally the 80 108 women who received a false positive diagnosis and had unnecessary follow-up procedures cost a total of 4.85 million USD (3.3% of the total IMSS CCSP cost) (table III and figure 1).
The one-way sensitivity analysis shows the relationship between the number of TP, FP and FN, and the coverage rate of the IMSS CCSP. When we varied the program coverage between 20 and 40%, these outcomes ranged from -32 to 35%. As the program coverage increases, we observe a corresponding increase in the number of FN and TP results, and a substantial increase in the number of FP (data not shown). Improving the sensitivity of the cytology test from 40 to 60% would help reduce the number of FN diagnoses, which is especially important to consider if the IMSS CCSP coverage were to increase from 20 to 40%. When the coverage is 20%, a sensitivity increase from 40 to 60% reduces the number of FN by 13%. At a coverage of 40% and a sensitivity of 60% the number of FN is reduced by 38.5% (data not shown). This reduction in FN does not result in a corresponding decrease in costs, but rather a slight increase of 0.37% is obseved (from 196.79 to 197.51 million USD). This is because a higher Pap sensitivity also increases the number of TP cases and their treatment costs.
Figure 2 presents the results of a three-way sensitivity analysis that examined how varying the coverage rates (20, 30 and 40%), sensitivity (35 vs. 60%) and costs (low, no change, and high) affects the base case total cost estimates. Our findings suggest that the scenario of high coverage (40%) and high sensitivity (60%) costs approximately 197.6 million and the scenario with high coverage (40%) and low sensitivity (35%) costs slightly less (196.7 million). FN make up the largest portion of total costs when the test sensitivity is low, and TP are the largest portion of total program costs, when the test sensitivity is high. If unitary costs are assumed to be low, total costs are reduced by 27.3% and if costs are high, total costs increase by 20 percent.
We estimated the total annual cost of the IMSS CCSP, which currently relies on cervical cytology as its primary diagnostic tool. To determine the total cost of the program, we considered the costs to perform a cytology test, follow-up procedures such as colposcopy and biopsy, as well as treatment costs. We also determined the number of TP, FN, FP and TN and calculated the costs associated with these outcomes. Our results indicate that the annual cost of the IMSS CCSP is approximately 145.4 million USD and that FN account for nearly 42.6% of the total program costs. We used the national coverage rate reported by the IMSS CCSP (29.53%) to estimate that 2.7 million Pap tests were performed in 2010, at a cost of nearly 38 million USD, which represents 26.1% of the total IMSS CCSP costs. The cost of the follow-up tests that were performed on women who received a TP diagnosis was estimated to be 4.9 million USD which is only 3.3%of the total program costs. As expected, we found that the high cost of treating women with CIN 2/3 or cervical cancer (102.8 million USD) is the greatest contributing factor to the cost of the IMSS CCSP (70.7%). The cost of cervical cancer-related diagnostic tests, consultations, hospitalizations, and medicines reported by IMSS to the President and Congress was estimated at 53.60 million USD.27 This amount is higher than our estimate of 37.87 million USD, which is likely conservative since it is 27% less than the official amounts reported by IMSS.
One of the main goals of this study was to provide precise estimates of the outcomes and costs associated with cytology, colposcopy and biopsy testing, and how they contribute to the total costs of the IMSS CCSP. The main expenditures include staff wages, followed by supply, overhead and capital costs. However, when we examined the aggregated costs and economic effect of the program, we found that the largest expense of the program is incurred by the treatment of FN and TP. The two main parameters allowing for variation of total costs were the sensitivity of cytology and the coverage of the program. Increasing coverage while maintaining a sensitivity of 40% leads to a corresponding increase in program costs. Although increasing the sensitivity of cytology reduces the cost of FN, it does not change the overall costs of the program significantly, due to the added cost of treating TP cases.
The results of our three-way sensitivity analyses suggest that higher coverage rates increase program costs due to additional diagnostic tests and increased treatment costs for both TP and FN. When the sensitivity of the cytology test is low, the FN cases represent the greatest proportion of program costs; but when the test sensitivity is high, the TP make up the largest portion of total program costs. These findings indicate that the performance of the IMSS CCSP could be improved without a significant cost increase.
The results of our study may be useful in determining ways to improve the cost management in the diagnosis of cervical cancer, however, the present study has some limitations. One limitation is that we did not estimate the costs associated with the time in which staff are not performing tasks explicitly for the program, i.e. "lost" time. We also did not estimate the total cost of the personnel involved in IMSS CCSP activities (not just the time they dedicate to program activities) based on different methods (such as number of personnel in a defined physical area or the step down method). This would have allowed us to determine the effect that the productivity of the IMSS CCSP staff has on the costs of the program. Another limitation of the study is that all information to determine costs was collected at one IMSS hospital. In order to investigate the effect of modifications of the costs of staff on total costs of the program we conducted a one way sensitivity analysis and found that the variation of total costs by varying staff costs by 20% appear to be not significant (4.7%). Further studies that collect information from different IMSS hospitals may help determine any possible differences in costs and cervical cancer prevalence. An additional limitation is the lack of information on the methodology used to determine treatment costs. This information was taken from a previous study and we do not know the methods used, and therefore cannot determine the quantity of goods and the individuals costs used for these estimations. We are, therefore uncertain as to how these costs are comparable to the costs of the diagnostic tests. As a result, we recommend additional studies to validate the treatment costs we used. Finally, one of our main assumptions is that cases are distributed in the same porportions (88% for CIN 2/3 and 12% for cervical cancer), whether they are TP or FN. However, additional studies are needed to determine if FN cases are more likely to be advanced and more expensive.
The results of our cost analysis suggest that the Pap test may not be an efficient screening strategy for the IMSS CCSP. Although the Pap test is not necessarily expensive at 14.00 USD per test, its notoriously low sensitivity generates high numbers of false negative diagnoses that result in high treatment costs, which represents the largest percentage of the annual IMSS CCSP cost (42.6%). Our findings confirm those of other studies, which report that conventional cytology is less accurate and effective than the HPV test or liquid-based cytology, which results in higher program costs in the long run.28-30 Finding ways to improve the impact of the IMSS CCSP is very important, especially because cervical cancer is a leading cause of death in Mexico. Our study shows that improvements such as increasing the sensitivity of the cytology test to 60% and the extending the coverage of the IMSS CCSP to 40%, would detect a much greater number of women with disease, without a substantial increase in program costs. Achieving these improvements is very unlikely, which is why policy and decision makers at IMSS should consider other options, such as incorporating HPV testing into the national CCSP to help reduce the burden of cervical cancer in Mexico.
We would like to thank Dr. Irma Fernandez from the Coordinación de Programas Integrados de Salud of IMSS, for providing the information regarding the national and regional coverage rates of the IMSS CCSP.
1. Almonte M, Murillo R, Sánchez GI, Jerónimo J, Salmerón J, Ferreccio C, et al. New paradigms and challenges in cervical cancer prevention and control in Latin America. Salud Publica Mex 2010;52(6):544-559.
2. Flores YN, Bishai DM, Lorincz A, Shah KV, Lazcano-Ponce E, Hernández M, et al. HPV testing for cervical cancer screening appears more cost-effective than Papanicolaou cytology in Mexico. Cancer Causes Control 2011;22(2):261-272.
3. Ditzian LR, David-West G, Maza M, Hartmann B, Shirazian T, Cremer M. Cervical cancer screening in low- and middle-income countries. Mt Sinai J Med 2011;78(3):319-326.
4. Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jerónimo J, et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008;26 suppl 11:L37-48.
5. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004;100(5):1035-1044.
6. Safaeian M, Solomon D, Castle PE. Cervical cancer preventioncervical screening: science in evolution. Obstet Gynecol Clin North Am 2007;34(4):739-760.
7. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systemic analysis. Lancet 2011;387:1461-1484.
8. Hernández-Peña P, Lazcano-Ponce EC, Alonso-de Ruiz P, Cruz-Valdez A, Meneses-González F, Hernández-Avila M. Análisis costo beneficio del programa de detección oportuna del cáncer cervicouterino. Salud Publica Mex 1997;39:379-387.
9. Lazcano-Ponce EC, Buiatti E, Nájera-Aguilar P, Alonso de Ruíz P, Hernández-Avila M. Evaluation model of the Mexican national program for early cervical cancer detection and proposals for a new approach. Cancer Causes Control 2001;9:1-11.
10. Chu KC, Miller BA, Springfield SA. Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. J Natl Med Assoc 2007;99(10)1092-1104.
11. Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, Hernández-Avila M. Regional differences in breast and cervical cancer mortality in Mexico between 1979-2006. Salud Pub Mex 2009; 51(2):S208-S219.
12. Gakidou E, Nordhagen S, Obemeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008;5:e132.
13. Sasieni P, Cuzick J, Farmery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet 1995;346(8989):1566-1567.
14. IARC Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J (Clin Res Ed) 1986;293(6548):659-664.
15. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127(12):2893-2917.
16. Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009;40(6):503-513.
17. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007;26(1):128-139.
18. Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, de la Rosa AP, Witlen R. Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective. Salud Publica Mex 2008;50(2):107-118.
19. Informe al Ejecutivo Federal y al Congreso de la Unión sobre la situación financiera y los riesgos del IMSS 2011-2012. 2012. IMSS. México [consulted 2013 May]. Available at: http://www.imss.gob.mx/instituto/informes/pages/index.htm
20. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, et al. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control 2010;21(10):1693-1700.
21. Salmerón J, Lazcano-Ponce E, Lorincz A, Hernández M, Hernández P, Leyva A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003;14(6):505-512.
22. Drummond M, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programs. Oxford: Oxford University Press, 1995.
23. Catálogo Delegacional de Recursos Humanos. Subdirección General de Recursos Humanos. México: Instituto Mexicano del Seguro Social, 2007.
24. Catálogo Delegacional de Consumibles. Emitido por la Coordinación de Abastecimiento y Equipamiento de la Delegación Morelos IMSS. México: Instituto Mexicano del Seguro Social 2006.
25. Catálogo Delegacional de Bienes Inmuebles. Subdirección General de Obras y Patrimonio Inmobiliario. México: Instituto Mexicano del Seguro Social 2007.
26. Instituto Mexicano del Seguro Social. Unitary costs by level of health care for 2013 to be used for fiscal purposes and tariffs for persons who are not insured by IMSS [consulted 2013 July]. Available at: http://www.portalfiscal.com.mx/pagina/principal/transferencias%20dof/varios/2013/IMSS/Costos%20de%20atencion%20medica%202013.htm
27. Informe al Ejecutivo Federal y al Congreso de la Unión sobre la situación financiera y los riesgos del IMSS 2010-2011. 2011. IMSS. México [consulted 2013 May]. Available at: http://18.104.22.168/estadisticas/financieras/Pages/InformeEjecutivo20102011.aspx
28. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012;344:e670.
29. Kim JJ, Wright TC , Goldie SJ. Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Insti 2005; 97(12):888-895.
30. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 2012;106: 1571-1578.
Received on: July 23, 2013
Accepted on: July 16, 2014
Dra. Yvonne Flores.
Unidad de Investigación Epidemiológica y en Servicios de Salud,
Instituto Mexicano del Seguro Social.
Blvd. Benito Juárez 31, col. Centro. 62000 Cuernavaca, Morelos, México.
Declaration of conflict of interests. The authors declare that they have no conflicts of interest.
* Unidad de Salud Pública. Coordinación de Programas Integrados en Salud (USP-CPIS 2010). Cobertura del programa tamizaje de cáncer cervico-uterino por estados. México: IMSS, 2011. Documento no publicado.